Salvia BioElectronics, a clinical-stage medical device company based in Eindhoven, has successfully raised €53 million in a Series B financing round. The funding, primarily led by Innovation Industries, aims to propel the company towards the completion of clinical trials and prepare for the launch of MySalvia Therapy for chronic migraines. Moreover, it will facilitate necessary FDA approvals and regulatory processes in Europe and Australia. With existing treatment options often falling short, Salvia's innovative approach promises to provide significant relief to millions suffering from chronic migraines.
Salvia BioElectronics is redefining the migraine therapy landscape with a bold, patient-centered approach that combines cutting-edge neuromodulation with an elegant, minimally invasive design.
We invest in breakthrough technologies that have the potential to solve the most pressing real-world challenges, and Salvia BioElectronics does exactly that: offering life-changing solutions for millions.
Migraine is one of the leading causes of disability worldwide, resulting in an estimated $110B annually in lost productivity and medical costs in the EU and US.
Current treatment options do not always provide sufficient relief, with the majority of chronic patients discontinuing their medication within the first year, highlighting the urgent need.
Collection
[
|
...
]